ArticleBMC biotechnology2026
Untargeted GC-MS metabolic profiling of Eurotium chevalieri AUMC 16390 (PX498623) reveals a putative steroidal metabolite with antibacterial and anti-inflammatory potential.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study investigated the exometabolome bioactive metabolites produced by Eurotium chevalieri AUMC 16,390 (accession number PX498623), a strain identified through ITS rDNA sequencing with 100% identity. The aim was to characterize its chemical profile and evaluate the biological activities of its major constituents. MATERIALS AND
methodsMetabolites present in the crude extract were analyzed using GC–MS, and ten major compounds were detected, spanning esters, diketones, terpenoids, and halogenated hydrocarbons. A predominant putative steroid-like metabolite, tentatively identified as 12-hydroxy-(5α,12β)-androstane-3,17-dione, accounted for 35.79% of the extract. Antibacterial activity of the crude extract was assessed against multiple bacterial strains. To elucidate potential mechanisms, molecular docking studies were conducted targeting enoyl-acyl carrier protein reductase (FabI). Additionally, the anti-inflammatory potential of the major steroidal compound was examined via predicted interactions with the glucocorticoid receptor (GR). Physicochemical and pharmacokinetic properties were evaluated using SwissADME.
resultsThe crude extract demonstrated broad-spectrum antibacterial activity. Docking analysis revealed favorable binding affinities of the major steroid-like metabolite toward FabI, supporting its potential antibacterial mechanism. The compound also showed high predicted affinity for the GR, suggesting possible anti-inflammatory activity. SwissADME results indicated acceptable drug-likeness features and favorable oral bioavailability parameters.
conclusionEurotium chevalieri AUMC 16,390 represents a promising source of bioactive fungal metabolites. The major putative steroidal component exhibits strong potential as an antimicrobial and anti-inflammatory agent, providing a foundation for future experimental validation and development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.